Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Champions Oncology (CSBR) over the last 15 years, with Q4 2025 value amounting to $6.0 million.

  • Champions Oncology's Accounts Payables rose 2346.52% to $6.0 million in Q4 2025 from the same period last year, while for Oct 2025 it was $6.0 million, marking a year-over-year increase of 2346.52%. This contributed to the annual value of $4.2 million for FY2025, which is 2675.86% down from last year.
  • As of Q4 2025, Champions Oncology's Accounts Payables stood at $6.0 million, which was up 2346.52% from $4.8 million recorded in Q3 2025.
  • Over the past 5 years, Champions Oncology's Accounts Payables peaked at $6.0 million during Q4 2025, and registered a low of $1.7 million during Q1 2021.
  • In the last 5 years, Champions Oncology's Accounts Payables had a median value of $4.6 million in 2022 and averaged $4.2 million.
  • In the last 5 years, Champions Oncology's Accounts Payables crashed by 3968.15% in 2021 and then skyrocketed by 12700.04% in 2023.
  • Quarter analysis of 5 years shows Champions Oncology's Accounts Payables stood at $3.5 million in 2021, then soared by 32.44% to $4.6 million in 2022, then decreased by 1.5% to $4.5 million in 2023, then rose by 7.01% to $4.9 million in 2024, then increased by 23.47% to $6.0 million in 2025.
  • Its Accounts Payables was $6.0 million in Q4 2025, compared to $4.8 million in Q3 2025 and $4.2 million in Q2 2025.